The plasma levels of FGF19 were significantly decreased in T2DM and obese patients, while injection of recombinant FGF19 protein significantly improved metabolic disorders in db/db mice and DIO mice (Guo et al., 2022). This evidence concerns the gene FGF19 and type 2 diabetes mellitus.